Rhumbline Advisers Acquires 3,745 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)

Rhumbline Advisers increased its holdings in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 6.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 62,700 shares of the company’s stock after buying an additional 3,745 shares during the period. Rhumbline Advisers owned 0.09% of Kiniksa Pharmaceuticals International worth $1,393,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of KNSA. Braidwell LP increased its stake in Kiniksa Pharmaceuticals International by 19.3% in the fourth quarter. Braidwell LP now owns 3,452,447 shares of the company’s stock valued at $68,289,000 after purchasing an additional 557,934 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Kiniksa Pharmaceuticals International by 138.9% in the fourth quarter. JPMorgan Chase & Co. now owns 477,800 shares of the company’s stock valued at $9,451,000 after purchasing an additional 277,827 shares in the last quarter. Millennium Management LLC increased its stake in Kiniksa Pharmaceuticals International by 50.9% in the fourth quarter. Millennium Management LLC now owns 779,672 shares of the company’s stock valued at $15,422,000 after purchasing an additional 263,146 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Kiniksa Pharmaceuticals International in the fourth quarter valued at approximately $3,955,000. Finally, Hudson Bay Capital Management LP increased its stake in Kiniksa Pharmaceuticals International by 150.0% in the fourth quarter. Hudson Bay Capital Management LP now owns 225,000 shares of the company’s stock valued at $4,450,000 after purchasing an additional 135,000 shares in the last quarter. Institutional investors own 53.95% of the company’s stock.

Insider Activity

In related news, COO Eben Tessari sold 17,300 shares of the stock in a transaction on Monday, June 16th. The shares were sold at an average price of $28.28, for a total transaction of $489,244.00. Following the completion of the transaction, the chief operating officer now owns 61,563 shares in the company, valued at approximately $1,741,001.64. This represents a 21.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Sanj K. Patel sold 2,872 shares of the stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $27.03, for a total transaction of $77,630.16. Following the transaction, the chief executive officer now owns 96,674 shares of the company’s stock, valued at $2,613,098.22. The trade was a 2.89% decrease in their position. The disclosure for this sale can be found here. Insiders sold 440,863 shares of company stock worth $12,101,029 over the last quarter. 53.48% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

KNSA has been the subject of several recent analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals International in a research note on Wednesday, April 16th. Citigroup initiated coverage on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, March 13th. They issued a “buy” rating and a $40.00 target price for the company. Jefferies Financial Group upped their target price on shares of Kiniksa Pharmaceuticals International from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Tuesday, April 29th. Finally, Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “buy” rating in a report on Saturday, June 14th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Kiniksa Pharmaceuticals International presently has a consensus rating of “Buy” and a consensus target price of $38.80.

Kiniksa Pharmaceuticals International Stock Down 0.1%

Kiniksa Pharmaceuticals International stock opened at $27.93 on Thursday. The stock has a market capitalization of $2.04 billion, a PE ratio of -111.72 and a beta of 0.06. Kiniksa Pharmaceuticals International, plc has a twelve month low of $17.38 and a twelve month high of $30.69. The company has a 50 day moving average of $25.63 and a 200-day moving average of $22.29.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.09. The company had revenue of $137.79 million during the quarter, compared to analysts’ expectations of $128.35 million. Kiniksa Pharmaceuticals International had a negative net margin of 3.52% and a negative return on equity of 3.83%. The business’s quarterly revenue was up 72.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.25) earnings per share. Equities analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.